Skip to main content

Table 6 Summary of hereditary cancer registries data from tumor MMR analysis from suspected Latin America LS families

From: A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America

Latin American Institutions Number of families Number of individuals Age at CRC diagnosis (mean ± SD) Age at endometrial cancer diagnosis (mean ± SD) Clinical criteria MMR deficient (%) MMR non-deficient (%)
AMSII Revised Bethesda
Instituto Nacional de Enfermedades Neoplásicas (Lima, Peru)a 82 83 41(13.1) 52(9.01) 22 60 40(48.2) 43(51.8)
Centro de EnfermedadesNeoplasicas Oncovida (La Paz, Boliva)b 46 61 27.7(12.7) na 46 0 3(4.9) 58(95.1)
Instituto Nacional de Cancerología de México (Mexico City, Mexico)c 23 60 33(14.6) 37.5(12.02) 11 12 23(38.3) 37(61.7)
Hospital Privado Universitario de Cordoba (Cordoba, Argentina)c 6 6 43.3(8.7) NA 0 6 3(50.0) 3(50.0)
Total 157 210    79 78 69(32.8) 141(67.2)
  1. a: MMR deficiency analyzed based on IHC and/or MSI; b: MMR deficiency based on BAT-25 MSI marker; c: MMR deficiency based on IHC; NA: not applied; MMR: mismatch-repair; CRC: colorectal cancer; SD: standard deviation; IHC: immunohistochemistry; MSI: microsatellite instability; MSI-H: MSI-high; MSS: microsatellite stable
\